Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome.

Roboz GJ, Ritchie EK, Curcio T, Samuel M, Provenzano J, Segovia J, Christos PJ, Mathew S, Allen-Bard S, Feldman EJ.

Leuk Res. 2011 Apr;35(4):522-5. doi: 10.1016/j.leukres.2010.09.010. Epub 2010 Oct 16.

PMID:
20956016
2.

Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.

Roboz GJ, Ritchie EK, Curcio T, Provenzano J, Carlin R, Samuel M, Wittenberg B, Mazumdar M, Christos PJ, Mathew S, Allen-Bard S, Feldman EJ.

Cancer. 2008 Nov 1;113(9):2504-11. doi: 10.1002/cncr.23855.

3.

Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.

Vey N, Bosly A, Guerci A, Feremans W, Dombret H, Dreyfus F, Bowen D, Burnett A, Dennis M, Ribrag V, Casadevall N, Legros L, Fenaux P.

J Clin Oncol. 2006 Jun 1;24(16):2465-71. Epub 2006 May 1.

4.

Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.

Schiller GJ, Slack J, Hainsworth JD, Mason J, Saleh M, Rizzieri D, Douer D, List AF.

J Clin Oncol. 2006 Jun 1;24(16):2456-64. Epub 2006 May 1.

5.

A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes.

Wei W, Zhou F, Zhang Y, Guo L, Shi H, Hou J.

Leuk Res. 2012 Jun;36(6):715-9. doi: 10.1016/j.leukres.2011.12.023. Epub 2012 Jan 24.

PMID:
22277680
6.
7.

Arsenic and old lace: novel approaches in elderly patients with acute myeloid leukemia.

Roboz GJ.

Semin Hematol. 2008 Jul;45(3 Suppl 2):S22-4. doi: 10.1053/j.seminhematol.2008.07.005. Review.

PMID:
18760707
8.

Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients.

Zheng WL, Zhang GS, Xu YX, Shen JK, Dai CW, Pei MF.

Leuk Res. 2008 Feb;32(2):251-4. Epub 2007 Oct 24.

PMID:
17920679
9.

Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.

Kantarjian H, Beran M, Cortes J, O'Brien S, Giles F, Pierce S, Shan J, Plunkett W, Keating M, Estey E.

Cancer. 2006 Mar 1;106(5):1099-109.

10.
11.

A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.

Sekeres MA, Maciejewski JP, Erba HP, Afable M, Englehaupt R, Sobecks R, Advani A, Seel S, Chan J, Kalaycio ME.

Cancer. 2011 Mar 15;117(6):1253-61. doi: 10.1002/cncr.25686. Epub 2010 Oct 19.

12.

A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes.

Prébet T, Ducastelle S, Debotton S, Stamatoullas A, Deconinck E, Fruchart C, Gratecos N, Ifrah N, Dreyfus F, Fenaux P, Wattel E; Groupe Français des Myélodysplasies (GFM), France.

Hematol J. 2004;5(3):209-15.

PMID:
15167906
13.

Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.

Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A.

Ann Hematol. 2004 Aug;83(8):498-503. Epub 2004 May 20.

PMID:
15156346
14.
15.

Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).

Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, Dugan K, Lum B, Chin DL, Dewald G, Paietta E, Bennett JM, Rowe JM.

J Clin Oncol. 2004 Mar 15;22(6):1078-86. Erratum in: J Clin Oncol. 2004 Jul 1;22(13):2747.

16.

High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.

Beran M, Shen Y, Kantarjian H, O'Brien S, Koller CA, Giles FJ, Cortes J, Thomas DA, Faderl S, Despa S, Estey EH.

Cancer. 2001 Oct 15;92(8):1999-2015.

PMID:
11596013
17.

Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia.

Weihrauch MR, Staib P, Seiberlich B, Hoffmann M, Diehl V, Tesch H.

Leuk Lymphoma. 2004 Apr;45(4):699-704.

PMID:
15160942
18.

Combination chemotherapy with risk factor-adjusted dose attenuation for high-risk myelodysplastic syndrome and resulting leukemia in the multicenter study of the Japan Adult Leukemia Study Group (JALSG): results of an interim analysis.

Okamoto T, Kanamaru A, Shimazaki C, Motoji T, Takemoto Y, Takahashi M, Fukushima T, Takeshita A, Kusumoto GS, Kishimoto Y, Yorimitsu S, Tsukuda K, Uike N, Arima N, Ohno R.

Int J Hematol. 2000 Aug;72(2):200-5.

PMID:
11039669
19.

Continuous sequential infusion of fludarabine and cytarabine for elderly patients with acute myeloid leukaemia secondary to a previously diagnosed myelodysplastic syndrome.

Ferrara F, Palmieri S, Izzo T, Criscuolo C, Riccardi C.

Hematol Oncol. 2010 Dec;28(4):202-8. doi: 10.1002/hon.943.

PMID:
21136583
20.

Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia.

Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SM, Samaratunga IR, Grace R, Gover PA, Mufti GJ.

Br J Haematol. 1997 Dec;99(4):939-44.

PMID:
9432047
Items per page

Supplemental Content

Write to the Help Desk